Protection of Macaques against a SHIV with a Homologous HIV-1 Env and a Pathogenic SHIV-89.6P with a Heterologous Env by Vaccination with Multiple Gene-Deleted SHIVs  by Ui, Masahiro et al.
m
c
a
a
s
m
H
(
l
a
m
i
t
t
r
1
d
1
I
B
d
Virology 265, 252–263 (1999)
Article ID viro.1999.0049, available online at http://www.idealibrary.com on
0
C
AProtection of Macaques against a SHIV with a Homologous HIV-1 Env and a Pathogenic SHIV-
89.6P with a Heterologous Env by Vaccination with Multiple Gene-Deleted SHIVs
Masahiro Ui,* Takeo Kuwata,* Tatsuhiko Igarashi,*,1 Kentaro Ibuki,* Yasuyuki Miyazaki,* Iouly L. Kozyrev,*,1
Yoshimi Enose,* Toshihide Shimada,† Hiromi Uesaka,*,‡ Hiroshi Yamamoto,‡
Tomoyuki Miura,* and Masanori Hayami*,2
*Laboratory of Viral Pathogenesis, Institute for Virus Research, and †Department of Pathology and Tumor Biology,
Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan; and ‡Laboratory Animal Research Center,
Toyama Medical and Pharmaceutical University, Toyama 930-0152, Japan
Received May 4, 1999; returned to author for revision July 26, 1999; accepted October 13, 1999
To evaluate the potential of SHIVs as anti-HIV-1 live vaccines, we constructed two gene-deleted SHIVs, designated
SHIV-drn and SHIV-dxrn. The former lacks vpr/nef and the latter lacks vpx/vpr/nef. Four macaques that had been vaccinated
with SHIV-drn were challenged with SHIV-NM-3rN, which has an HIV-1 Env that is the same as that of SHIV-drn. No challenge
virus was detected by DNA PCR in, or recovered from, two of the macaques. In the other two, challenge virus was detected
once and twice, respectively. Plasma viral loads were much lower than those in unvaccinated controls. Another four
macaques were vaccinated with SHIV-dxrn. These macaques showed resistance but less than that of SHIV-drn-vaccinated
macaques. When the two SHIV-drn-vaccinated macaques were challenged with pathogenic SHIV-89.6P, which has an HIV-1
Env that is antigenically different from that of SHIV-drn, replication of the challenge virus was restricted, and the usual
decrease in the number of CD41 cells was prevented. In this protection, it is noteworthy that protection involved not only
neutralizing antibodies and killer cell activity, but also other unknown specific and nonspecific immunity elicited by the
infection. © 1999 Academic Press
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sINTRODUCTION
Many attempts have been made to develop anti-hu-
an immunodeficiency virus type 1 (HIV-1) vaccines to
ontrol the AIDS pandemic. However, the lack of a suit-
ble animal model is a major obstacle to developing
nti-HIV-1 vaccines because few animal species are
usceptible to HIV-1 infection. Chimpanzees are com-
only used for experimental infection, but the original
IV-1 hardly develops AIDS-like disease in chimpanzees
Nara et al., 1987; Novembre et al., 1997). Another prob-
em with chimpanzees is that they are not easily avail-
ble. We previously demonstrated that HIV-1/SIVmac chi-
eric viruses (SHIVs) that have HIV-1 Env and that are
nfectious to macaque monkeys are useful for evaluating
he efficacy of anti-HIV-1 vaccine candidates by using
hem as challenge viruses for vaccinated monkeys (Iga-
ashi et al., 1994, 1997; Kuwata et al., 1995; Shibata et al.,
991). So far, many SHIVs have been developed from
ifferent HIV-1 strains (Joag et al., 1997; Klinger et al.,
998; Kuwata et al., 1996; Li et al., 1992; Luciw et al., 1995;
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252eimann et al., 1996a,b), and vaccine efficacy against
hallenges with these SHIVs has been evaluated (Dunn
t al., 1997; Joag et al., 1998; Shibata et al., 1997; Ste-
hens et al., 1997).
Previous experience with viral vaccines, such as those
or poliomyelitis and measles, has proved that live atten-
ated vaccines are the most effective. Efforts to develop
nti-HIV-1 live vaccines have been carried out using
IV-1/chimpanzee and SIV/macaque animal model sys-
ems (for recent reviews see (Almond and Heeney, 1998;
esrosiers, 1998; Letvin, 1998). Chimpanzees infected
ith HIV-1 resisted superinfection with other HIV-1
trains (Fultz et al., 1987; Gibbs et al., 1991; Shibata et al.,
996). In the SIV/macaque system, attenuated SIVs pro-
ected vaccinees against challenge with not only anti-
enically homologous viruses (Almond et al., 1995; Con-
or et al., 1998; Daniel et al., 1992; Lohman et al., 1994;
arthas et al., 1990; Otsyula et al., 1996; Robinson et al.,
999; Stahl-Hennig et al., 1996; Van Rompay et al., 1996),
ut also heterologous viruses (Bogers et al., 1995; Clem-
nts et al., 1995; Dunn et al., 1997; Gibbs et al., 1991;
undlach et al., 1998; Letvin et al., 1995; Miller et al.,
997; Petry et al., 1995; Putkonen et al., 1995; Quesada-
olander et al., 1996; Shibata et al., 1997; Stephens et al.,
997). Based on the success of the SIV/macaque model
ystem, attenuated HIV-1s, which were constructed by
ene deletion or which were isolated from long-term
n
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253PROTECTIVE EFFECT OF GENE-DELETED SHIVsonprogressors, were proposed as vaccine candidates
Desrosiers, 1998; Johnson, 1999; Johnson and Desro-
iers, 1998; Letvin, 1998). However, the efficacy and
afety of these attenuated HIV-1s could not be evaluated
n animal models but only in humans and chimpanzees.
ecently we reported that attenuated SHIVs containing
IV-1 Env have potential as anti-HIV-1 vaccines for sev-
ral reasons (Haga et al., 1998; Hayami and Igarashi,
997; Hayami et al., 1999; Igarashi et al., 1997): (1) SHIVs
re able to induce humoral and cell-mediated immunity
irected to HIV-1 Env (Igarashi et al., 1997, 1994; Lekutis
nd Letvin, 1997; Voss and Letvin, 1996). (2) SHIVs can
nfect and replicate well in human peripheral blood
ononuclear cells (PBMCs) as well as in macaque PB-
Cs (Shibata et al., 1991), and thus induction of protec-
ive immunity could be expected in humans. (3) The
mmunity elicited against SIV Gag may be involved in
rotection against HIV-1 infection since SHIVs have SIV
ag which is antigenically cross-reactive with HIV-1 Gag
Carpio et al., 1991; Voss and Letvin, 1996). (4) SIVmac,
ne of the parental viruses of SHIVs, is considered non-
athogenic in humans because in accidentally infected
ersons the infection remained silent (CDC, 1997; Khab-
az et al., 1994, 1992). (5) Their efficacy and safety can be
valuated using macaques instead of humans (Sakuragi
t al., 1992; Shibata et al., 1991).
Deletion of genes which were shown to be associated
ith disease onset in the SIV/macaque system, such as
ef and vpr, is one possible approach to attenuating
iruses (Desrosiers, 1998; Desrosiers et al., 1998; Kestler
t al., 1991; Lang et al., 1993). We recently reported that
acaques vaccinated with vpr- and/or nef-defective
HIVs elicited anti-HIV-1 humoral and cell-mediated im-
unity and were protected against infection when chal-
enged with the gene-intact SHIV (Igarashi et al., 1997).
ased on this success, we newly constructed SHIVs
ompletely lacking these genes and reported their viro-
ogical and immunological properties in macaques until
bout 20 months after infection (Igarashi et al., 1998). In
his report, we further analyzed the long-term immuno-
ogical status of these vaccine viruses and their protec-
ive effect against infection when challenged with two
HIVs, SHIV-NM-3rN and SHIV-89.6P. The Env of SHIV-
M-3rN is homologous to that of the vaccine viruses,
hile the Env of SHIV-89.6P is antigenically different from
hat of the vaccine viruses. SHIV-89.6P is pathogenic and
rovokes a decrease in the number of CD41 cells early
fter infection.
RESULTS
irological and immunological status before challenge
Two groups, each consisting of four macaques, were
accinated with SHIV-drn or SHIV-dxrn (Fig. 1). Their
irological and immunological status up to 20 months
fter the vaccination was previously reported (Igarashi et el., 1998). Here we report their status after an additional
months. Table 1 summarizes the virological and immu-
ological status of these macaques after the vaccination
ust before the challenge with SHIV-NM-3rN. The SHIV-
rn-vaccinated macaques showed transient viremia (at 2
eeks post primary vaccination (w.p.v.)) after vaccination
ut no virus was recovered just before the challenge. No
irus was isolated from any of the SHIV-dxrn-vaccinated
acaques from the vaccination to the challenge. The
eak neutralizing antibody (NAb) titers before the chal-
enge and the NAb titers just before the challenge (at
12 w.p.v. of the SHIV-drn-vaccinated macaques and at
16 w.p.v. of SHIV-dxrn-vaccinated macaques) are also
hown in Table 1. Before the challenge, the presence of
Ab in the SHIV-drn-vaccinated macaques varied. MM81
etained NAb, which neutralized not only the parental
HIV-NM-3rN (Table 1), but also its parental HIV-1NL432
data not shown). MM86 and MM87 lost their NAb and
o NAb was detected in MM85 throughout the period
efore the challenge. Among the SHIV-dxrn-vaccinated
acaques, MM88 and MM103 had NAb as low as the
FIG. 1. Genomic structures of SHIVs used in this study. SHIV-drn,
HIV-dxrn, and NM-3rN were constructed from HIV-1NL432 and SIV-
ac239. Open and solid boxes are from SIVmac239 and HIV-1NL432,
espectively. Stippled boxes represent deleted genes. SHIV-drn lacks
pr and nef; SHIV-dxrn lacks vpr, nef, and vpx. The genomic structures
f challenge viruses are also shown. SHIV-89.6P was isolated from
acaques infected with in vivo-passaged SHIV-89.6 (Reimann et al.,
996a). SHIV-89.6 was constructed from HIV-1HXBc2 (shaded boxes),
IV-189.6 (lined boxes), and SIVmac239.nd point titer (203), and MM101 and MM102 had no
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254 UI ET AL.Ab. Three SHIV-drn-vaccinated macaques (MM85,
M86, and MM87) and two SHIV-dxrn-vaccinated ma-
aques (MM88 and MM103) had HIV-1 Env- and/or SIV
ag-specific killer cell activities that were more than 10%
Table 1). All vaccinated macaques except MM85 had NK
ell activities that were higher than those of normal
acaques, whose activities were lower than 10%. Thus,
n general, SHIV-drn-vaccinated macaques, in which the
accine virus replicated and from which it was recov-
red, showed higher immunity than SHIV-dxrn-vacci-
ated macaques, in which no evidence of vaccine virus
eplication was obtained.
rotection of SHIV-drn-vaccinated macaques against
hallenge with SHIV-NM-3rN
To evaluate the protective effect of SHIV-drn against a
hallenge with the SHIV having an HIV-1 Env homolo-
ous to that of SHIV-drn, the vaccinated macaques were
ntravenously challenged with SHIV-NM-3rN at about 2
ears postvaccination. All of the genes of SHIV-NM-3rN
ere intact, and its Env was homologous to that of
HIV-drn. As unvaccinated controls, two naive ma-
aques, MM125 and MM126, were also inoculated. For
wo of the four SHIV-drn-vaccinated macaques (MM85
nd MM86), no infectious virus was recovered and the
NA PCR remained negative in PBMCs throughout the
bservation period (Table 2). In MM81, the challenge
irus was detected by DNA PCR at 10 w.p.c. In MM87, the
hallenge virus was detected once by DNA PCR at
w.p.c. and isolated twice at 6 and 12 w.p.c., but the
ell-associated viral load of the challenge virus was
T
Virological and Immunological Status of SHIV-drn-
Vaccine Macaque
Virus isolationa
Anytime before
challenge
Just before
challenge
HIV-drn MM81 1 2
MM85 1 2
MM86 1 2
MM87 1 2
HIV-dxrn MM88 2 2
MM101 2 2
MM102 2 2
MM103 2 2
a (1) Vaccine virus was isolated; (2) no virus isolation. SHIV-drn was
ot isolated from any of the SHIV-dxrn-vaccinated macaques at any tim
b NAb titer against SHIV-NM-3rN.
c Activities were measured at 110 w.p.v. (at 11 w.p.v. for MM86). Valu
d NK activities of the SHIV-drn- and SHIV-dxrn-vaccinated macaques
f lysis of K562 cells. The E:T ratio was 50:1.bout 1/80 that in the naives. The vaccine virus was netected by DNA PCR at 8 w.p.c. in MM87. In the inguinal
ymph nodes (LNs) at 31 weeks postchallenge, no DNA
CR signal was detected in any of the macaques except
M87, in which the signal was proved by differential
CR to be the vaccine virus rather than the challenge
irus (Table 2). Figure 2 shows the plasma viral loads in
hese macaques, although the vaccine viruses and the
hallenge viruses could not be differentiated. The
lasma viral loads of all the SHIV-drn-vaccinated ma-
aques increased after the challenge, but were from
bout 1/200 to 1/4000 of those of the naives (Fig. 2). To
etermine the host response against viral replication
fter the challenge, the antibody titer was measured by
article agglutination. All the SHIV-drn-vaccinated ma-
aques except MM87 showed an anamnestic antibody
eaction to the challenge (data not shown). At 2 w.p.c.,
M81 and MM85 had significantly greater HIV-1 Env-
pecific killer cell activities (.10%) than did the naives,
nd at 2 and 4 w.p.c., MM85 had significantly greater SIV
ag-specific killer cell activities (.10%) than did the
aives, though MM81 did not have these activities before
he challenge (Table 3). Thus MM85 and MM86, which
ere vaccinated with SHIV-drn, showed almost complete
esistance since no challenge virus was recovered from
BMCs or detected by DNA PCR in PBMCs or LNs.
owever, the resistance was not perfect, as low viral
eplication was observed by plasma RT–PCR.
rotection of SHIV-dxrn-vaccinated macaques against
hallenge with SHIV-NM-3rN
The SHIV-dxrn-vaccinated macaques were intrave-
HIV-dxrn-Vaccinated Macaques before Challenge
utralizing antibodyb Specific killer cell
activityc
NK
activityd
efore
nge
Just before
challenge HIV-1 Env SIV Gag
0 1024 6.8 0 20.4
0 ,20 11.1 27.6 6.0
0 ,20 11.7 0 25.8
0 ,20 32.0 0 19.2
0 20 13.0 28.8 19.2
0 ,20 4.7 0 25.4
0 ,20 9.2 8.5 17.4
0 20 0 13.8 45.7
d from all the SHIV-drn-vaccinated macaques at 2 w.p.v. SHIV-dxrn was
ng the observation period.
w the percentage of specific lysis. The E:T ratio was 100:1.
easured at 83 and 87 w.p.v., respectively. Values show the percentageABLE 1
and S
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255PROTECTIVE EFFECT OF GENE-DELETED SHIVsostvaccination. The infectious challenge virus was not
ecovered from MM88 or MM102, but was recovered
rom MM101 once at 2 w.p.c. and from MM103 once at
w.p.c. (Table 2). Their cell-associated viral loads were
T
Challenge of SHIV-drn- and SHIV-dxr
Vaccine Macaque Method 2 4
HIV-drn MM 81 PCRa 2 2 2
VLb ,0.71 ND ,0
MM 85 PCR 2 2 2
VL ,0.38 ND ,0
MM 86 PCR 2 2 2
VL ,0.11 ND ,1
MM 87 PCR 2 2 1
VL ,0.56 ND 8
HIV-dxrn MM 88 PCR 2 1 1
VL ,0.77 ND ,2
MM 101 PCR 2 1 2
VL 31 ND ,3
MM 102 PCR 2 1 2
VL ,3.9 ND ,2
MM 103 PCR 2 2 2
VL ,0.53 ND 0
aive MM125 PCR 1 1 1
VL 629 ND 41
MM126 PCR 1 1 1
VL 1869 ND 208
Note. ND, Not determined.
a The 1 and 2 refer to detection of, or failure to detect, challenge v
b Cell-associated virus loads, i.e., number of virus producing cells/1
hallenge viruses.
c DNA PCR of inguinal LNs at 31 w.p.c.
d SHIV-drn was detected.
FIG. 2. Plasma viral loads of the vaccinated macaques after chal-
enge with NM-3rN. Plasma viral loads were measured by RT–PCR as
escribed under Materials and Methods. The vaccine viruses and thechallenge virus could not be differentiated.ess than 1/20 of those of the naives. No challenge virus
as detected by DNA PCR in MM103, but it was detected
n MM88, MM101, and MM102 sporadically (Table 2). In
he inguinal LNs of those macaques obtained at
1 w.p.c., neither the challenge virus SHIV-NM-3rN nor
he vaccine virus SHIV-dxrn was detected by DNA PCR.
lasma viral RNA was detected, but the plasma viral
oads were less than 1/160 of those of the naives (Fig. 2).
ll the SHIV-dxrn-vaccinated macaques showed an an-
mnestic antibody reaction against the challenge infec-
ion (data not shown). At 4 w.p.c., MM101 and MM103
howed significantly higher HIV-1 Env-specific killer
ell activities (.10%), and MM102 and MM103 showed
ignificantly higher SIV Gag-specific killer cell ac-
ivities (.10%) than did the naives, though MM101 and
M102 did not have these activities before the challenge
Table 3).
Thus, all the SHIV-dxrn-vaccinated macaques showed
ignificant but not complete resistance to infection of
HIV-NM-3rN having an HIV-1 Env homologous to that of
he vaccine virus. Compared with SHIV-drn, the SHIV-
xrn induced less protective immunity because two of
he four SHIV-drn-vaccinated macaques showed almost
nated Macaques with SHIV-NM-3rN
Weeks postchallenge
LNa,c8 10 12 16 24 30
2 1 2 2 2 2 2
ND ND ,1.0 ND ND ,0.76 ND
2 2 2 2 2 2 2
ND ND ,2.0 ND ND ,0.19 ND
2 2 2 2 2 2 2
ND ND ,4.0 ND ND ,0.95 ND
2d 2 2 2 2 2 2d
ND ND 2.1 ND ND ,0.56 ND
1 2 2 2 1 2 2
ND ND ,6.3 ND ND ,0.58 ND
1 2 2 2 2 1 2
ND ND ,1.4 ND ND ,0.45 ND
1 2 2 2 2 2 2
ND ND ,3.1 ND ND ,0.71 ND
2 2 2 2 2 2 2
ND ND ,1.6 ND ND ,0.16 ND
1 1 1 1 1 1 1
ND ND ,2.9 ND ND ,0.15 ND
1 1 1 1 1 1 1
ND ND 18 ND ND ,0.24 ND
DNA PCR.
D81 cell-depleted PBMCs. Isolated viruses were confirmed to be theABLE 2
n-Vacci
6
.56
.45
.6
.2
.3
.2
.4
.59
.5
irus by
3 106 Complete resistance.
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256 UI ET AL.rotection of SHIV-drn-vaccinated macaques against
hallenge with pathogenic SHIV-89.6P having
ntigenically heterologous HIV-1 Env
To further assess the vaccine efficacy, two of the
HIV-drn-vaccinated macaques, MM85 and MM86, were
ntravenously challenged with pathogenic SHIV-89.6P 36
eeks after the challenge with SHIV-NM-3rN (Fig. 1). The
nv of SHIV-89.6P is antigenically heterologous to that of
HIV-drn (Montefiori et al., 1998). These two macaques
reviously had shown strong resistance to the challenge
ith SHIV-NM-3rN. Before the challenge with SHIV-89.6P,
he plasmas from MM85 and MM86 were unable to
eutralize SHIV-89.6P (data not shown) and the specific
iller cell activity against HIV-189.6 Env was not examined.
s a control, two naive macaques, MM142 and MM144,
ere also inoculated with SHIV-89.6P. The challenge
irus was recovered from MM86 at 8 w.p.c. (Table 4) but
as not detected by DNA PCR in the PBMCs. In MM85,
he virus was detected at 3 w.p.c., which was delayed
ompared with the naives, and the infectious virus was
ecovered only twice at 2 and 3 w.p.c. Their plasma viral
oads measured by RT–PCR were about 1/60,000 of that
f the naives (Fig. 3a).
T
HIV-1 Env- and SIV Gag-Specific Killer Cell Activities of SHIV-dr
Vaccine Macaque Target cella ch
HIV-drn MM81 HIV-1 Env
SIV Gag
MM85 HIV-1 Env
SIV Gag
MM86 HIV-1 Env
SIV Gag
MM87 HIV-1 Env
SIV Gag
HIV-dxrn MM88 HIV-1 Env
SIV Gag
MM101 HIV-1 Env
SIV Gag
MM102 HIV-1 Env
SIV Gag
MM103 HIV-1 Env
SIV Gag
aive MM125 HIV-1 Env
SIV Gag
MM126 HIV-1 Env
SIV Gag
Note. ND, Not determined.
a BLCL infected with a VV-expressing HIV-1 Env or SIV Gag.
b At 110 w.p.v. (11 w.p.v. for MM86).
c Values show the percentage of specific lysis. The E:T ratio was 10In addition, we analyzed the change in the number of wD41 cells in these macaques after the challenge, be-
ause the challenge virus SHIV-89.6P is known to be
athogenic, causing a decrease in the number of CD41
ells (Reimann et al., 1996a). The two unvaccinated ma-
aques showed equally rapid decreases in the number
f CD41 cells after the challenge with SHIV-89.6P, reach-
ng less than 10% after 3 w.p.c. (Fig. 3b), in agreement
ith previous reports (Karlsson et al., 1997; Reimann et
l., 1996a; Steger et al., 1998). In contrast, the vaccinated
acaques did not show any decrease in the number of
D41 cells and were healthy during the observation
eriod (.30 w.p.c.). Thus, the SHIV-drn-vaccinated ma-
aques partly resisted the challenge infection of the
athogenic SHIV having HIV-1 Env heterologous to that
f SHIV-drn, but did not suffer any loss of CD41 cells.
his suggested that the vaccine virus might be effective
gainst disease progression, even if the challenge virus
scapes and infects the vaccinated macaques.
DISCUSSION
In this study, we examined the protective effect of two
ene-deleted SHIVs against challenges with the homol-
gous and heterologous SHIVs. When the vaccinees
SHIV-dxrn-Vaccinated Macaques after Challenge with NM-3rN
Specific killer cell activityc
b
w.p.c.
2 4 10 30
13.4 0.0 0.0 0.0
0.0 12.1 13.8 8.2
18.4 14.1 ND 4.9
28.8 19.1 ND 16.7
ND ND 9.0 7.3
ND ND 23.4 4.1
ND 5.0 ND 18.8
0.0 2.7 ND 13.6
15.3 ND 3.9 1.8
0.0 ND 19.8 21.5
0.0 32.0 5.9 15.6
0.0 7.9 2.1 5.6
ND 0.0 5.2 18.2
ND 31.4 9.8 5.5
ND 9.4 8.7 14.6
ND 20.6 15.8 11.5
5.9 0.2 3.9 4.8
0.0 13.5 0.0 36.3
4.5 10.3 13.8 38.9
0.4 10.7 0.0 9.6ABLE 3
n- and
Before
allenge
6.8
0.0
11.1
27.6
11.7
0.0
32.0
0.0
13.0
28.8
4.7
0.0
9.2
8.5
0.0
13.8
0.0
1.3
1.6
2.7ere challenged with homologous SHIV-NM-3rN, two of
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257PROTECTIVE EFFECT OF GENE-DELETED SHIVsour SHIV-drn-vaccinated macaques (MM85 and MM86)
howed almost complete resistance. The other two
HIV-drn-vaccinated macaques also resisted the chal-
enge because their plasma and cell-associated viral
oads were lower than those of the unvaccinated con-
T
Cell-Associated Viral Loads and DNA PCR in SHIV-d
Vaccine Macaque Method 0 1 2
HIV-drn MM 85 PCRa 2 2 2
VLb ,0.19 ,0.71
MM 86 PCR 2 2 2
VL ,0.95 ,0.38 ,
aive MM142 PCR 2 1 1
VL ND 33 262
MM144 PCR 2 1 1
VL ND 5 6
Note. ND, Not determined.
a The 1 and 2 refer to detection of, or failure to detect, proviral SH
b Cell-associated viral loads, i.e., number of virus producing cells/1
FIG. 3. Challenge of SHIV-drn-vaccinated macaques with SHIV-89.6P.
a) Plasma viral loads after the challenge. Plasma viral loads were
easured by RT–PCR as described under Materials and Methods. The
accine virus and the challenge virus could not be differentiated. (b)
hanges in the number of circulating CD41 cells with time. Values are
xpressed as a percentage of the number of CD41 cells of each1acaque just before the challenge, as described by Steger et al. (1998).rols. Thus, SHIV-drn induced strong protection. All the
HIV-dxrn-vaccinated macaques showed less resis-
ance than did the SHIV-drn-vaccinated macaques. Still,
heir plasma viral loads were less than 1/160 and their
ell-associated viral loads were less than 1/20 of those
f the unvaccinated macaques. In all these vaccinated
acaques, replication of the challenge virus either did
ot occur or was transient, and no challenge virus was
etected in the LNs. Viral replication in LNs was reported
o be associated with disease progression (Pantaleo et
l., 1993, 1994, 1995).
The macaques vaccinated with SHIV-NM-3 and SHIV-
M-3n had humoral and/or cell-mediated immunity and
ere protected against challenge with SHIV-NM-3rN
Igarashi et al., 1997). The more effective protection pro-
ided by SHIV-NM-3 and SHIV-NM-3n may be related to
he fact that they replicated well, because these SHIVs
nfected rhesus macaques persistently (Igarashi et al.,
997, 1994), while SHIV-drn and SHIV-dxrn showed tran-
ient or no viremia. The present results suggested that
HIV-dxrn was less effective than SHIV-drn. Our results
how that as more genes are deleted, the replication,
mmunogenicity, and protective effect decrease. These
esults are in agreement with the results of other studies
f SIVs lacking one to five genes, such as nef, vpr, vpx,
TR, and vif (Desrosiers, 1998; Kestler et al., 1991; Lang et
l., 1993). SHIV-dxrn, which showed no evidence of rep-
ication in the inoculated macaques, might have been
verattenuated. None of the macaques inoculated with
HIV-drn or SHIV-dxrn showed any symptoms associ-
ted with disease.
There is presently some controversy over whether
umoral immunity (e.g., immunity provided by anti-viral
eutralizing antibodies) or cell-mediated immunity (e.g.,
mmunity provided by specific killer cells) has a more
mportant role in protection (Johnson and Desrosiers,
cinated Macaques after Challenge with SHIV-89.6P
w.p.c.
3 4 6 8 10 12
1 1 1 1 1 1
726 ,0.71 ,0.71 ,0.83 ,0.32 ,0.14
2 2 2 2 2 2
,0.71 ,0.83 ,1.0 1.0 ,3.7 ,0.36
1 1 1 1 1 1
ND 1094 10 14 ND ,0.06
1 1 1 1 1 1
ND 14 17 27 ND 3.3
by DNA PCR.
CD81 cell-depleted PBMCs.ABLE 4
rn-Vac
9
1.0
4
6
IV-89.6P998; Shibata et al., 1997). Before being challenged, two
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258 UI ET AL.HIV-drn-vaccinated macaques that showed strong re-
istance to homologous SHIV-NM-3rN (MM85 and
M86) had no NAb, but they did have HIV-1 Env- and/or
IV Gag-specific killer cell activities. However, MM87,
hich also had no NAb but which had higher killer cell
ctivities, was not as well protected as MM85 and
M86. In addition, MM81, which had a high level of NAb
ut no specific killer cell activity, was less protected
gainst the challenge virus, although the degree of pro-
ection was still significant. Therefore, we could not de-
ermine in this study which kinds of immunity played
mportant roles in protection. It is noteworthy that MM101
nd MM102, which were vaccinated with SHIV-dxrn and
hich had neither detectable NAb nor specific killer cell
ctivity, showed less but significant resistance. It is likely
hat several defense mechanisms are involved in this
rotection. These mechanisms would include not only
ell-known immunity, such as anti-viral neutralizing an-
ibody and specific killer cell activity, but also unknown
pecific and nonspecific defense mechanisms, such as
ntibody-dependent cell cytotoxicity (ADCC), NK cell ac-
ivity, and others. NK cell activity was detected in most of
he macaques vaccinated with SHIV-drn and SHIV-dxrn.
omplex specific and nonspecific immunities elicited by
atural infection might contribute cooperatively to pro-
ection (Dittmer et al., 1999). This is one of the reasons
ttenuated live vaccines are expected to be most effec-
ive.
Since HIV-1 is known to be highly divergent, a vaccine
ust be able to protect against not only homologous
IV-1 but also divergent HIV-1 strains. We showed that
HIV-drn provided some protection against challenge
ith SHIV-89.6P, which has an HIV-1 Env that is antigeni-
ally different from that of SHIV-drn. Since the infectious
hallenge virus, SHIV-89.6P, was isolated only once from
ne of two SHIV-drn-vaccinated macaques that were
hallenged with SHIV-89.6P (MM86), and the two ma-
aques had significantly lower plasma viral loads, we
onclude that SHIV-drn showed resistance against the
hallenge with SHIV-89.6P. As these macaques showed
o NAb against SHIV-89.6P and their specific killer cell
ctivity could not be examined in this study, we were
nable to determine which kinds of immunity might be
nvolved in this cross-resistance. In addition to the pos-
ibility of cross-reactive CTL, ADCC and other mecha-
isms mediated via antibodies might play a role where
ross-recognition in the absence of neutralization might
ccur. Besides, nonspecific defense mechanisms such
s NK activity and cytokines, including chemokines,
ight be involved in this cross-resistance. It might be
lso possible that different coreceptor usage between
HIV-drn, which utilizes only CXCR4 (data not shown),
nd SHIV-89.6P, which utilizes both CXCR4 and CCR5
Karlsson et al., 1998), might influence the result. In any
ase, our results demonstrated that the gene-deleted
HIVs could provide partial protection against infection pf an SHIV having antigenically heterologous HIV-1 Env.
here are several reports on protection against heterol-
gous challenge using a SIV/SHIV combination and, as
hown in this study, some of these experiments were
uccessful (Bogers et al., 1995; Dunn et al., 1997; Miller et
l., 1997; Quesada-Rolander et al., 1996; Stephens et al.,
997).
Even if SHIV-drn vaccination did not provide the two
acaques with complete protection against infection
ith SHIV-89.6P, it did prevent a decrease in the number
f circulating CD41 cells by SHIV-89.6P in both of them.
his prevention might result from restricting the replica-
ion of the challenge virus, as shown in Table 2. Joag et
l. (1998) reported that immunization with vaccine SHIVs
ith deletion(s) of vpu and/or nef prevented the decrease
n number of CD41 cells after intravaginal inoculation
ith a pathogenic SHIVKU-1 having an HIV-1 Env homolo-
ous to those of vaccine viruses. In HIV infection, a
igher viral load is associated with more advanced dis-
ase progression (Iuliano et al., 1997). Watson et al.
1997) and Ten Haaft et al. (1998) reported that SIV- or
HIV-infected macaques which had higher plasma viral
oads survived for shorter times. We suggest that the low
iral loads of the challenge virus in the SHIV-drn-vacci-
ated macaques might prevent the decrease in the num-
er of circulating CD41 cells. Therefore, it is possible
hat the gene-deleted SHIV might prevent the progres-
ion of the disease even if the challenge virus escapes
nd replicates.
Many studies have been carried out to develop anti-
IV-1 vaccines. We previously suggested that live atten-
ated vaccines are the most effective type of protection
gainst infection because they can induce complex in-
ection immunity consisting of specific humoral and cel-
ular immunity and nonspecific immunity in macaques
Igarashi et al., 1997), as shown in this study. Previously
e proposed that SHIVs are good starting materials for
aking anti-HIV-1 live vaccines for human use (Haga et
l., 1998; Hayami and Igarashi, 1999; Hayami et al., 1999;
garashi et al., 1997). One of the reasons is that these
accines can be expected to induce protective immunity
n humans as well as in macaques, because SHIVs can
eplicate not only in macaque PBMCs but also in human
BMCs. However, we must be careful in applying the
ata obtained in monkeys directly to humans. For atten-
ation, in this study we deleted two or three genes,
ncluding nef, which was reported to be associated with
athogenicity in the SIV/macaque system and in humans
f the Sydney Blood Bank Cohort (Deacon et al., 1995;
estler et al., 1991). However, similar gene-deleted SIVs
ere recently reported to be pathogenic in neonates and
ven in adult macaques that had been infected for pro-
onged periods of time (Baba et al., 1995, 1999). These
eports claimed that attenuation by gene deletion is not
atisfactory for assuring safety. But the safety of the
arental SHIV-NM-3rN, from which the gene-deleted
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259PROTECTIVE EFFECT OF GENE-DELETED SHIVsHIVs used in this study were derived, was confirmed to
e nonpathogenic during 3 years of observation and
ecause five in vivo passages failed to make the virus
athogenic. Further modification of SHIVs by other ap-
roaches will be required to make a much safer live
ttenuated vaccine.
MATERIALS AND METHODS
accine viruses and challenge viruses
Two gene-deleted SHIVs that had been constructed
rom SHIV-NM-3rN (Kuwata et al., 1995) were used for
accine viruses (Igarashi et al., 1998). One, SHIV-drn,
as lacking nef and vpr, and the other, SHIV-dxrn, was
acking nef, vpr, and vpx. Figure 1 shows the genomic
tructures of these gene-deleted SHIVs. They contain
nv, tat, rev, and vpu derived from HIV-1NL432 (Adachi et
l., 1986) and LTRs, gag, pol, vif, and/or vpx derived from
IVmac239 (Kestler et al., 1990). SHIV-drn has deletions
n the 59 portion, including the initiation codons of nef
nd vpr. A splicing acceptor for vpr was modified so that
t would not function. SHIV-dxrn was constructed by de-
eting the 39 portion of vpx in addition to the deletion of
HIV-drn. The initiation codon of vpx was modified to a
on-sense codon. Stocks of these gene-deleted SHIVs
ere prepared for macaque inoculation using M8166
ells (a subclone of C8166 (Clapham et al., 1987)) as
escribed previously (Kuwata et al., 1995).
SHIV-NM-3rN (Kuwata et al., 1995) and pathogenic
HIV-89.6P (Karlsson et al., 1997; Reimann et al., 1996a)
ere used for challenge (Fig. 1). SHIV-89.6P was kindly
rovided by Dr. K. A. Reimann (Harvard Medical School).
HIV-NM-3rN, the parental SHIV from which the gene-
eleted SHIVs were made, is nonpathogenic, having
IV-1NL432 Env, which is the same as that of the vaccine
iruses SHIV-drn and SHIV-dxrn. SHIV-89.6P is derived
rom in vivo-passaged SHIV-89.6. This virus has HIV-189.6
nv, which is antigenically different from that of the
accine viruses (Montefiori et al., 1998) and causes a
apid decline of CD41 cell numbers and AIDS-like dis-
ases in inoculated macaques (Reimann et al., 1996b).
tocks of these challenge viruses were prepared for
acaque inoculation using rhesus macaque PBMCs, as
escribed previously (Kuwata et al., 1995). The TCID50 of
hese virus stocks were determined as previously de-
cribed (Igarashi et al., 1994).
nimals
Mature male rhesus macaques (Macaca mulatta) neg-
tive for SIV and simian T-cell lymphotropic virus type 1,
ere used. All the monkeys were housed throughout the
xperimental period and autopsies and biopsies were
arried out in accordance with regulations approved by
he Institutional Animal Care and Use Committee of the
nstitute for Virus Research, Kyoto University. taccination and challenge inoculation
Two groups of four macaques were vaccinated intra-
enously with 1 3 105 TCID50 of SHIV-drn or SHIV-dxrn,
espectively. To assess the acquisition of immunological
emory induced by the first inoculation, the macaques
ere reinoculated with 1 3 107 TCID50 of each vaccine
irus at 68 w.p.v. as reported previously, and three of four
HIV-drn-vaccinated macaques and none of the SHIV-
xrn-vaccinated macaques showed an anamnestic anti-
ody reaction (Igarashi et al., 1998).
SHIV-drn- and SHIV-dxrn-vaccinated macaques were
ntravenously inoculated with 100 TCID50 of SHIV-NM-
rN at 112 and 116 w.p.v., respectively. Thirty-six weeks
ater, two SHIV-drn-vaccinated macaques, MM85 and
M86, were inoculated intravenously with 10 TCID50 of
HIV-89.6P. This dose was based on preliminary exper-
ments that showed that, for each virus, about 1/10 the
riginal dose was the minimal amount needed to induce
iremia in macaques (unpublished data). PBMCs of all of
he macaques were prepared by Percoll density gradient
entrifugation (Pharmacia) and used for the analyses
escribed below. The separated plasma was subjected
o RT–PCR and antibody assays. Inguinal LNs were ob-
ained from all of the macaques for DNA PCR analysis at
1 w.p.c. with NM-3rN. LNs were obtained by biopsy of
M85 and MM86 and by autopsy of the others.
irus recovery and infectious virus loads in PBMCs
The infectious cell-associated viral load was deter-
ined as described previously (Kestler et al., 1991).
riefly, serial threefold dilutions of periodically collected
D81 cell-depleted PBMCs were cocultured with 1 3 106
8166 cells for 4 weeks in RPMI 1640 medium supple-
ented with 10% heat-inactivated fetal bovine serum
GIBCO-BRL), 20 mM L-glutamine, and 10 mM sodium
yruvate. Virus recovery was judged by the syncytial
ytopathic effect and the expression of viral antigens
etected by an indirect immunofluorescence assay. Cell-
ssociated viral loads were expressed as the number of
irus-producing cells per 1 3 106 CD8-depleted PBMCs.
etection and differentiation of viral genomes in
BMCs by DNA PCR
To detect viruses and to differentiate vaccine or chal-
enge viruses after the challenges, DNA PCR was carried
ut. The primers that were used in this study can amplify
he central region of the viral genome, including vpr and
px, which were deleted in the vaccine viruses. The
tructure of this region was different between SHIV-NM-
rN and SHIV-89.6P (Kuwata et al., 1995; Reimann et al.,
996a). Thus, PCR amplification with the above primers
an differentiate SHIV-drn, SHIV-dxrn, SHIV-NM-3rN, and
HIV-89.6P by the length of the PCR product. Cells and
6issues (1 3 10 PBMCs, LNs at 31 w.p.c., and M8166
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260 UI ET AL.ells infected with the isolated virus) were lysed by
ncubating them in 100 ml of Proteinase K buffer (10 mM
ris–HCl, pH 8.0, 1 mM EDTA, pH 8.0, 0.001% Triton
-100, 0.0001% SDS, 600 mg/ml Proteinase K) for 1 h at
6°C, followed by incubation for 15 min at 95°C. These
ysates were used for detection of the proviral genome.
he PCR was carried out using AmpliTaq DNA polymer-
se (Perkin–Elmer) in a total volume of 50 ml. The primers
ere DF1 (59-ATCCCACCTGGAAACAGTGGAGAAGAGA-
A-39) and DR1 (59-CAAGCAGTTTTAGGCTGACTTCCTG-
ATGC-39) for the first PCR and DF2 (59-CGGTAAACCAC-
TACCAAGGGAGCTAATTT-39) and DR2 (59-GTAACGC-
TATTCTGCTATGTCGACACCCA-39) for the nested PCR.
amples were first denatured at 94°C for 9 min, followed
y 35 cycles consisting of denaturation at 94°C for 1 min,
nnealing at 58°C for 1 min, and elongation at 72°C for
min, with a final elongation at 72°C for 5 min. The PCR
roducts were analyzed on a 2% agarose gel.
uantitation of plasma viral loads
Plasma viral loads after the challenges were deter-
ined by RT–PCR. RT reactions and PCRs were per-
ormed by a Taqman RT–PCR kit (Perkin–Elmer) (Sur-
anarayana et al., 1998) using RNA samples (corre-
ponding to 40 ml of plasma) prepared by Viral RNA kit
QIAGEN) and the primers SIVII-696F (59-GGAAATTAC-
CAGTACAACAAATAGG-39) and SIVII-784R (59-TCTAT-
AATTTTACCCAGGCATTTA-39). A labeled probe, SIVII-
31 (59-Fam-TGTCCACCTGCCATTAAGCCCG-Tamra-39,
erkin–Elmer), was used for detection of 59-nuclease
ctivity. For each run, a standard curve was generated
rom dilutions of an in vitro transcript containing gag. The
T–PCR system amplifies both the challenge and vac-
ine viruses and cannot differentiate these viruses. Un-
er these conditions, the detection limit was 250 copy/
l.
etection and titration of neutralizing antibody and
article-agglutinating antibody
Neutralizing antibody was assessed by the method of
garashi et al. (1994). Samples of SHIV-NM-3rN or SHIV-
9.6P (100 TCID50) were treated with twofold serial dilu-
ions of the plasma samples. The virus was considered
eutralized when RT activity was reduced to no more
han half that in normal macaque plasma. Antibody titer
fter the challenge with SHIV-NM-3rN was measured by
article agglutination according to the manufacturer’s
nstructions (Serodia HIV, Fujirebio).
IV-1 Env- or SIV Gag-specific killer cell activities and
K cell activity
HIV-1 Env- or SIV Gag-specific killer cell activities were
easured by the method of Yamamoto et al. (1990) as
odified by Igarashi et al. (1997). Herpesvirus papio-ransformed B cell lines (BLCL) derived from PBMCs ofach macaque were infected with vaccinia viruses (VVs)
xpressing the Env of HIV-1 (HIV-1IIIb) or SIV Gag (from
IVmac239) and were used for target cells to measure
nv- or Gag-specific killer cell activities, respectively.
arental vaccinia virus-infected and noninfected cells
ere used as control targets. To measure NK activity,
562 cells were used as target cells. Env- or Gag-spe-
ific killer cell activity was expressed as the percentage
f specific lysis when the effector:target cell ratio was
00:1. This was the percentage of parental VV-infected
LCL that were lysed subtracted from the that of the
IV-1 Env- or SIV Gag-expressing BLCL that were lysed.
K activity was expressed as the percentage of K562
ells that were lysed when this ratio was 50:1. The
ctivity was regarded as significant when more than 10%
f the cells were lysed.
ymphocyte phenotyping
CD41 cell numbers in PBMCs isolated from the ma-
aques were calculated after the challenge with SHIV-
9.6P. PBMCs were treated with anti-CD4 antibody (Nu-
H/I-PE; NICHIREI) and examined on a FACScan ana-
yzer (Becton–Dickinson) according to the manufacturer’s
ecommendations. Absolute lymphocyte counts in the
lood were determined with an automated blood cell
ounter (F-820; Sysmex). The percentages of CD41 cells
emaining were calculated as described by Steger et al.
1998). The number of CD41 cells of each macaque just
efore the challenge was defined as 100%.
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